Erdosteine: Its relevance in COPD treatment

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 3, 2009, Pages 333-343

  Moretti, Maurizio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Antioxidative treatment; Chronic bronchitis; Chronic obstructive pulmonary disease; Erdosteine; Mucolytic agent; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ACETYLCYSTEINE; AMBROXOL; AMOXICILLIN; ANTIBIOTIC AGENT; CARBOCISTEINE; CIPROFLOXACIN; ERDOSTEINE; MUCOLYTIC AGENT; ANTIOXIDANT; EXPECTORANT AGENT; THIOGLYCOLIC ACID DERIVATIVE; THIOPHENE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HOSPITALIZATION; HUMAN; LONG TERM CARE; OXIDATIVE STRESS; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; ANIMAL; BRONCHITIS; PATHOPHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; BRONCHITIS; CLINICAL TRIALS AS TOPIC; EXPECTORANTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THIOGLYCOLATES; THIOPHENES;

EID: 65549110824     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902814790     Document Type: Review

References (47)

1. Pauwels RA, Buist AS, Calverley PM, et al. GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276 (Pubitemid 32378468)
2. MacNee W. Oxidants/antioxidants and COPD. Chest 2000;117:303S-17S (Pubitemid 30327005)
3. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:65-376 (Pubitemid 19106873)
4. Rahman I, MacNee W. Oxidant/antioxidant imbalance in smokers and in chronic obstructive pulmonary disease. Thorax 1996;51:348-350 (Pubitemid 26140195)
5. Sandford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997;10:1380-1391 (Pubitemid 27278264)
6. Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055-1060 (Pubitemid 126679546)
7. Finiguerra M, Conti P, Figura I, et al. Clinical study on the effects of an antibiotic and mucolytic association (amoxicillin and domiodol) in hypersecretory chronic bronchopulmonary diseases. Curr Ther Res 1982;31:895-905
8. Peralta J, Poderoso JJ, Corazza C, et al. Ambroxol plus amoxicillin in the treatment of xacerbations of chronic bronchitis. Arzneimittelforschung 1987;37:969-971 (Pubitemid 17135349)
9. Bolser DC. Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):238S-49S; review (Pubitemid 43265228)
10. Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;3:CD001287
11. Busin S. Erdosteine: evaluation of mucorheological and immunosecretory parameters in patients with bronchial phlogistic pathology. Med Praxis 1991;12:197-205
12. Marchioni CF, Moretti M, et al. Effects of erdosteine on sputum biochemical and rheologic properties: pharmacokinetics in chronic obstructive lung disease. Lung 1990;168:285-293 (Pubitemid 20364628)
13. Olivieri D, Del Donno M, Casalini A, et al. Respiration 1991;58:91-94
14. Scuri R, Giannetti P, Paesano A. Effect of erdosteine and its metabolites on tracheobronchial mucus production and transport. Drug Exp Clin Res 1988;14:693-698 (Pubitemid 19089941)
15. Braga PC. Dal Sasso M, Sala MT, et al. Effects of erdosteine and its metabolites on bacterial adhesiveness. Arzneim-Forsch/Drug Res 1999;49:344-350 • Shows the erdosteine antibacterial activity in vitro. (Pubitemid 29198114)
16. Miyake K, Kaise T, Hosoe H, et al. The effect of erdosteine on reactive oxygen species production by inflammatory cells. Inflamm Res 1999;48:205-209
17. Hosoe H, Kaise T, Ohmori K. Effects on the reactive oxygen species of erdosteine and its metabolite in vitro. Arzneimittel 2002;52:435-440 (Pubitemid 34628063)
18. Braga PC, Dal Sasso M, Zuccotti T. Assessment of the antioxidant activity of the SH Metabolite 1 of erdosteine on human neutrophils respiratory burst. Arzneim Forsch Drug Res 2000;50:739-746 • Details the erdosteine antioxidative activity in vitro.
19. Moretti M, Marchioni CF. An overview of erdosteine antioxidant activity in experimental research. Pharmacol Res 2007;55:249-254 • Overview of erdosteine antioxidant activity in an animal study. (Pubitemid 46533932)
20. Basyigit I, Yildiz F, Cekmen M, et al. Effects of erdosteine on smoking-induced lipid peroxidation in healthy smokers. Drugs R 2005;6:83-89 (Pubitemid 40485252)
21. Dal Negro RW, Visconti M, Micheletto C, et al. Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: a controlled study in current smokers with mild COPD. Pulm Pharmacol Ther 2008;21:304-308 • Details the antioxidative and antiinflammatory activity of erdosteine in COPD active smokers. (Pubitemid 351320569)
22. Dal Negro RW, Visconti M, Trevisan F, et al. Erdosteine enhances airway response to salbutamol in patients with mild-tomoderate COPD. Ther Adv Respir Dis 2008;2:271-277
23. Dal Negro RW, Visconti M, Tognella, et al. Erdosteine affects eicosanoid production in asthma and COPD. Eur Resp J 2008;32 (Suppl 52):364s
24. Ricevuti G, Mazzone A, Uccelli E, et al. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis. Thorax 1988;43:585-590 • Erdosteine incresases amoxicillin penetration into sputum. (Pubitemid 18207749)
25. Bisetti A, Mancini C. Mucolytic activity of erdosteine double blind clinical trial vs placebo. Archivio di Medicina Interna 1995;47:89-97 (Pubitemid 26320467)
26. Marchioni CF, Polu JM, Taytard A, et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Intern J Clin Pharmacol Ther 1995;33:612-618 • Adding erdosteine to standard treatment significantly modifies the outcome of CB and COPD acute exacerbation.
27. Mohanty KC, Thiappanna G, Sing V, Mancini C. Evaluation of efficacy and safety of erdosteine in patients affected by exacerbation of chronic bronchitis and receiving ciprofloxacin as basic treatment. J Clin Research 2001;4:35-39 (Pubitemid 32721162)
28. Fumagalli G. Erdosteine: a new molecule with mucolytic activity. Clinical and instrumental evaluation in patients with acute and exacerbated chronic bronchopneumopathies. Ital. J Chest Dis 1988;42:299-308
29. Tellings JC. Erdosteine: original secretolytic drug with mucociliar activity: a controlled clinical study versus ambroxol. Med Praxis 1991;12:183-195
30. Franco M, Mancini C. Controlled clinical study of erdosteine in chronic bronchitic patients. Archivio di Medicina Interna 1995;47:101-111 (Pubitemid 26320468)
31. Zanasi A, Menarini A. Erdosteine versus N-acetylcysteine in the treatment of exacerbation of chronic bronchopneumopathies. Med Praxis 1991;12:207-217
32. Haughney J, Grishchenko M, Dakin HA, et al. Cost-effectiveness of erdosteine in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Thorax 2007;62 (Suppl III):A47
33. Morice A, Moretti M, Ballabio M. Erdosteine in association with amoxicillin improves the outcome of acute exacerbations compared to amoxicillin alone in COPD patients. Thorax 2007;62 (Suppl III):A47
34. Ghiringhelli G, Mancini C. Cross-over study of efficacy and tolerability of erdosteine in the treatment of chronic obstructive bronchial disease in stable hypersecretive phase: Controlled double-blind study vs placebo. Archivio di Medicina Interna 1995;67:113-120 (Pubitemid 26320469)
35. Aubier M, Berdah L. Etude multicentrique, controllèe en double aveugle, de l'efficacité et de la tolerance de vectrine (erdosteine) versus placebo dans le traitement de la bronchite chronique hypersecretante tabilisée. Rev Mal Respir 1999;16:521-528 (Pubitemid 29484963)
36. Fioretti M, Bandera M. Prevention of exacerbations in chronic bronchitic patients with erdosteine. Med Praxis 1991;12:219-227
37. Moretti M, Bottrighi P, Dallari R, et al. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res 2004;30:143-152 • Positive effects of an 8-month treatment with erdosteine in COPD patients. (Pubitemid 39487682)
38. Greenberg SB, Allen M, Wilson J, et al. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:167-173 (Pubitemid 30469815)
39. Keistinen T, Tuuponen T, Kivela SL, Survival experience of the population needing hospital treatment for asthma or COPD at age 50-54 years. Respir Med 1998;92:568-572 (Pubitemid 28162173)
40. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422 (Pubitemid 28242071)
41. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002:57:847-852 (Pubitemid 35178607)
42. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S (Pubitemid 30111556)
43. Moretti M, Assereto R. The effect of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients. Eur Respir J 2006;28 (suppl 50):765s
44. Dal Sasso M, Culici M, Guffanti EE, et al. A combination of budesonide and the SH-metabolite I of erdosteine acts synergistically in reducing chemiluminescence during human neutrophil respiratory burst. Pharmacology 2005;74:127-134 (Pubitemid 40981098)
45. Mancini C. Erdosteine, the second generation mucolytic: international up-dating of clinical studies (adult and pediatrics). Archivio di Medicina Interna 1996;48:53-59
46. Dechant KL, Noble S. Erdosteine. Drugs 1996;52(6):875-881
47. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;176;454-459